Blueprint Medicines CorpNASDAQ:BPMC
- LAST PRICE105.2100
- TODAY'S CHANGE (%)-1.5000 (-1.4057%)
- Bid / Lots104.0000/ 2
- Ask / Lots110.9500/ 3
- Open / Previous Close105.8100 / 106.7100
- Day Range
- 52 Week Range
- Volume430,314
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BPMC |
|---|---|---|
| 09:32 ET | 3880 | 105.81 |
| 09:34 ET | 200 | 105.105 |
| 09:38 ET | 220 | 105.1008 |
| 09:39 ET | 450 | 105.98 |
| 09:41 ET | 300 | 105.823 |
| 09:43 ET | 4466 | 107.18 |
| 09:45 ET | 3984 | 106.075 |
| 09:48 ET | 1030 | 106.045 |
| 09:50 ET | 417 | 105.99 |
| 09:52 ET | 100 | 105.6 |
| 09:54 ET | 300 | 105.905 |
| 09:56 ET | 300 | 106.37 |
| 09:57 ET | 200 | 105.91 |
| 09:59 ET | 100 | 105.98 |
| 10:01 ET | 500 | 105.985 |
| 10:03 ET | 500 | 105.68 |
| 10:06 ET | 300 | 105.855 |
| 10:08 ET | 300 | 105.865 |
| 10:10 ET | 200 | 105.52 |
| 10:12 ET | 1000 | 105.41 |
| 10:14 ET | 333 | 104.96 |
| 10:15 ET | 100 | 104.8 |
| 10:17 ET | 100 | 105.015 |
| 10:19 ET | 2494 | 105.015 |
| 10:21 ET | 300 | 105.08 |
| 10:24 ET | 100 | 105.105 |
| 10:26 ET | 618 | 104.85 |
| 10:28 ET | 900 | 105.225 |
| 10:30 ET | 200 | 105.32 |
| 10:32 ET | 578 | 105.333 |
| 10:33 ET | 951 | 105.29 |
| 10:35 ET | 335 | 105.255 |
| 10:37 ET | 852 | 105.165 |
| 10:39 ET | 1416 | 105.37 |
| 10:42 ET | 100 | 105.38 |
| 10:44 ET | 1441 | 105.03 |
| 10:46 ET | 400 | 104.935 |
| 10:48 ET | 300 | 104.72 |
| 10:50 ET | 100 | 104.73 |
| 10:51 ET | 200 | 104.71 |
| 10:53 ET | 574 | 104.925 |
| 10:55 ET | 200 | 104.66 |
| 10:57 ET | 235 | 104.955 |
| 11:00 ET | 100 | 104.97 |
| 11:02 ET | 200 | 104.77 |
| 11:04 ET | 1788 | 104.95 |
| 11:06 ET | 300 | 104.835 |
| 11:08 ET | 100 | 104.66 |
| 11:09 ET | 605 | 104.83 |
| 11:11 ET | 700 | 104.865 |
| 11:15 ET | 1189 | 105.17 |
| 11:18 ET | 100 | 105.19 |
| 11:20 ET | 406 | 105 |
| 11:22 ET | 1213 | 104.725 |
| 11:24 ET | 333 | 104.76 |
| 11:26 ET | 2303 | 104.76 |
| 11:27 ET | 1423 | 104.67 |
| 11:29 ET | 300 | 104.34 |
| 11:31 ET | 600 | 104.4 |
| 11:33 ET | 434 | 104.31 |
| 11:38 ET | 2500 | 104.57 |
| 11:40 ET | 1713 | 104.47 |
| 11:44 ET | 3018 | 104.74 |
| 11:45 ET | 700 | 104.725 |
| 11:49 ET | 1150 | 104.63 |
| 11:51 ET | 338 | 104.575 |
| 11:54 ET | 10405 | 104.415 |
| 11:56 ET | 632 | 104.53 |
| 11:58 ET | 4817 | 103.93 |
| 12:00 ET | 200 | 103.58 |
| 12:02 ET | 700 | 103.6778 |
| 12:03 ET | 800 | 103.7 |
| 12:05 ET | 1034 | 103.645 |
| 12:07 ET | 4808 | 103.775 |
| 12:09 ET | 100 | 103.86 |
| 12:12 ET | 2004 | 103.94 |
| 12:14 ET | 925 | 104.05 |
| 12:16 ET | 239 | 104 |
| 12:18 ET | 469 | 104 |
| 12:20 ET | 835 | 103.92 |
| 12:21 ET | 933 | 103.965 |
| 12:23 ET | 300 | 103.77 |
| 12:25 ET | 356 | 103.86 |
| 12:27 ET | 400 | 103.76 |
| 12:30 ET | 1205 | 103.9 |
| 12:32 ET | 100 | 103.725 |
| 12:34 ET | 600 | 103.9 |
| 12:36 ET | 100 | 103.725 |
| 12:38 ET | 600 | 103.625 |
| 12:41 ET | 623 | 103.83 |
| 12:43 ET | 900 | 104.09 |
| 12:45 ET | 445 | 103.895 |
| 12:48 ET | 600 | 103.89 |
| 12:52 ET | 200 | 103.88 |
| 12:54 ET | 1142 | 103.88 |
| 12:56 ET | 700 | 103.73 |
| 12:57 ET | 200 | 103.755 |
| 12:59 ET | 100 | 103.74 |
| 01:01 ET | 100 | 103.775 |
| 01:03 ET | 400 | 103.71 |
| 01:06 ET | 200 | 103.53 |
| 01:08 ET | 2901 | 103.85 |
| 01:10 ET | 100 | 103.785 |
| 01:12 ET | 500 | 103.79 |
| 01:14 ET | 2334 | 103.77 |
| 01:15 ET | 600 | 103.66 |
| 01:17 ET | 200 | 103.65 |
| 01:19 ET | 434 | 103.6 |
| 01:21 ET | 19389 | 103.84 |
| 01:24 ET | 471 | 103.82 |
| 01:26 ET | 134 | 103.81 |
| 01:28 ET | 900 | 103.575 |
| 01:30 ET | 500 | 103.42 |
| 01:32 ET | 710 | 103.5 |
| 01:33 ET | 1720 | 103.26 |
| 01:35 ET | 100 | 103.31 |
| 01:37 ET | 2050 | 103.22 |
| 01:39 ET | 700 | 103.245 |
| 01:42 ET | 200 | 103.245 |
| 01:44 ET | 2642 | 103.5 |
| 01:48 ET | 414 | 103.25 |
| 01:50 ET | 800 | 103.57 |
| 01:51 ET | 400 | 104.07 |
| 01:53 ET | 600 | 104.4 |
| 01:55 ET | 1320 | 104.545 |
| 01:57 ET | 100 | 104.44 |
| 02:00 ET | 1074 | 104.435 |
| 02:02 ET | 2651 | 104.83 |
| 02:04 ET | 932 | 105.015 |
| 02:06 ET | 100 | 105.22 |
| 02:08 ET | 600 | 105.295 |
| 02:09 ET | 400 | 105.2 |
| 02:11 ET | 800 | 105.26 |
| 02:13 ET | 640 | 105.13 |
| 02:15 ET | 2750 | 104.86 |
| 02:18 ET | 680 | 104.765 |
| 02:20 ET | 100 | 104.76 |
| 02:22 ET | 1133 | 105.11 |
| 02:24 ET | 100 | 105.185 |
| 02:26 ET | 700 | 105.46 |
| 02:27 ET | 358 | 105.55 |
| 02:29 ET | 436 | 105.78 |
| 02:31 ET | 400 | 105.95 |
| 02:36 ET | 667 | 105.78 |
| 02:38 ET | 300 | 105.64 |
| 02:40 ET | 200 | 105.48 |
| 02:42 ET | 2104 | 105.16 |
| 02:44 ET | 200 | 105.195 |
| 02:45 ET | 500 | 105.195 |
| 02:47 ET | 300 | 105.215 |
| 02:49 ET | 1339 | 105.35 |
| 02:51 ET | 1295 | 105.29 |
| 02:54 ET | 700 | 105.15 |
| 02:56 ET | 268 | 105.225 |
| 02:58 ET | 635 | 105.14 |
| 03:00 ET | 1469 | 105.29 |
| 03:02 ET | 500 | 105.44 |
| 03:03 ET | 1016 | 105.01 |
| 03:05 ET | 600 | 104.905 |
| 03:07 ET | 737 | 104.845 |
| 03:09 ET | 1000 | 105.1 |
| 03:12 ET | 238 | 105.1 |
| 03:14 ET | 1723 | 105.13 |
| 03:16 ET | 300 | 105.36 |
| 03:18 ET | 100 | 105.35 |
| 03:20 ET | 806 | 105.07 |
| 03:21 ET | 200 | 104.93 |
| 03:23 ET | 900 | 105.105 |
| 03:25 ET | 900 | 105.2125 |
| 03:27 ET | 200 | 105.3 |
| 03:30 ET | 438 | 105.235 |
| 03:32 ET | 300 | 105.215 |
| 03:34 ET | 3648 | 105.57 |
| 03:36 ET | 9297 | 105.47 |
| 03:38 ET | 900 | 105.255 |
| 03:39 ET | 900 | 105.35 |
| 03:41 ET | 554 | 105.205 |
| 03:43 ET | 700 | 105.11 |
| 03:45 ET | 1711 | 104.78 |
| 03:48 ET | 800 | 104.9 |
| 03:50 ET | 3585 | 104.985 |
| 03:52 ET | 1578 | 104.93 |
| 03:54 ET | 2146 | 105.14 |
| 03:56 ET | 3264 | 105.15 |
| 03:57 ET | 4016 | 105.145 |
| 03:59 ET | 59363 | 105.21 |
Yesterday
Jun 19, 2024
The Schall Law Firm Is At Present Probing Potential Securities Law Violations For Investors Of Blueprint Medicines Corporation, from 4:36PM ET on Wednesday Jun 19, 2024 by Dow Jones
4:36PM ET on Wednesday Jun 19, 2024 by Dow Jones
Jun 17, 2024
Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC), from 8:33PM ET on Monday Jun 17, 2024 by Dow Jones
8:33PM ET on Monday Jun 17, 2024 by Dow JonesAt Present The Schall Law Firm Is Conducting Investigations Into Potential Violations Of Securities Laws For The Advantage Of Blueprint Medicines Corporation (NASDAQ:BPMC) Investors, from 8:19PM ET on Monday Jun 17, 2024 by Dow Jones
8:19PM ET on Monday Jun 17, 2024 by Dow Jones
Jun 13, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Blueprint Medicines Corp | 6.7B | -21.8x | --- |
Legend Biotech Corp | 7.4B | -15.7x | --- |
Ascendis Pharma A/S | 7.2B | -12.7x | --- |
Revolution Medicines Inc | 6.2B | -10.0x | --- |
Cytokinetics Inc | 6.0B | -9.6x | --- |
CRISPR Therapeutics AG | 5.1B | -22.1x | --- |
Company Information
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Contact Information
- Headquarters
- 45 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-374-7580
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jeffrey Albers
- President, Chief Executive Officer, Director
- Kathryn Haviland
- Chief Financial Officer
- Michael Landsittel
- President - Research and Development
- Fouad Namouni
- Chief Operating Officer
- Christina Rossi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.7B |
|---|---|
Revenue (TTM) | $282.2M |
Shares Outstanding | 62.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.63 |
EPS | $-4.82 |
Book Value | $2.14 |
P/E Ratio | -21.8x |
Price/Sales (TTM) | 23.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -94.69% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
